Literature DB >> 16424823

Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms.

Vibhuti Srivastava1, Panchami G Varma, Suman Prasad, Prachi Semwal, Vishwajit L Nimgaonkar, Bernard Lerer, Smita N Deshpande, Thelma BK.   

Abstract

OBJECTIVE: Tardive dyskinesia (TD) is an antipsychotic induced side effect observed in 20-30% of schizophrenia subjects on long-term typical antipsychotic treatment. We tested the possible association of 24 polymorphisms from six dopaminergic genes: namely, dopamine receptors D1, D2, D3, D4; the dopamine transporter (DAT); and the catalyzing enzyme catechol-O-methyltransferase (COMT), with TD.
METHODS: Multiple SNP/VNTR markers from candidate genes were analyzed using suitable approaches and allelic, genotypic and haplotypic associations were tested.
RESULTS: 120 bp duplication marker, 1.2 kb upstream from initiation codon of DRD4 gene showed a significant genotypic association [chi2 = 9.29, P = 0.009; OR (95% CI) = 0.52 (0.31-0.86) for genotype 120 dup/120 dup]. In the COMT gene, a significant allelic [chi2 = 13.87, P = 0.0002] as well as genotypic association [chi2 = 16.08, P = 0.0003; OR (95% CI) = 0.24 (0.11-0.55) for genotype GG] was observed with the 408 C>G (exon 4) single nucleotide polymorphism and a significant genotypic association [chi2 = 6.32, P = 0.04; OR (95% CI) = 0.50 (0.33-0.92) for genotype GG] was observed with 472 G > A (exon 4, Val 158 Met) SNP. 120 bp dup-T-repeat 3 in DRD4 and G-C-A-insC in COMT genes were observed to be TD associated haplotypes.
CONCLUSIONS: Our study presents a detailed analysis of the possible role of dopaminergic genes in the genesis of TD. DRD4 and COMT genes were observed to be the most important candidates in North Indian schizophrenia subjects. These suggestive associations need to be investigated in replicate studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16424823     DOI: 10.1097/01.fpc.0000184957.98150.0f

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  19 in total

Review 1.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

2.  Analysis of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia.

Authors:  I-Ching Lai; Geng-Han Mo; Mao-Liang Chen; Ying-Chieh Wang; Jen-Yeu Chen; Ding-Lieh Liao; Ya-Mei Bai; Chao-Cheng Lin; Tzu-Ting Chen; Ying-Jay Liou
Journal:  Eur J Clin Pharmacol       Date:  2010-12-22       Impact factor: 2.953

3.  Genetic susceptibility to Parkinson's disease among South and North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes and association of DRD4 120-bp duplication marker.

Authors:  Ramesh C Juyal; Mitashree Das; Sohan Punia; Madhuri Behari; Geetika Nainwal; Sumit Singh; Pazhayannur V Swaminath; Shyla T Govindappa; Sachi Jayaram; Uday B Muthane; B K Thelma
Journal:  Neurogenetics       Date:  2006-07-01       Impact factor: 2.660

4.  Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genes.

Authors:  B K Thelma; Arun K Tiwari; Smita N Deshpande; Bernard Lerer; Vishwajit L Nimgaonkar
Journal:  Schizophr Res       Date:  2007-02-21       Impact factor: 4.939

5.  Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.

Authors:  Cüneyt Güzey; Maria Gabriella Scordo; Edoardo Spina; Veslemøy Malm Landsem; Olav Spigset
Journal:  Eur J Clin Pharmacol       Date:  2007-01-17       Impact factor: 2.953

Review 6.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

Review 7.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

8.  Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients.

Authors:  Chiara Fabbri; Daniel Souery; Raffaella Calati; Concetta Crisafulli; Armando Chierchia; Diego Albani; Gianluigi Forloni; Alberto Chiesa; Rosalba Martines; Othman Sentissi; Julien Mendlewicz; Giovanni De Girolamo; Alessandro Serretti
Journal:  J Neural Transm (Vienna)       Date:  2014-08-17       Impact factor: 3.575

9.  A Meta-analysis of the Association Between SLC6A3 Gene Polymorphisms and Schizophrenia.

Authors:  Feng-Ling Xu; Mei Ding; Xue Wu; Yong-Ping Liu; Xi Xia; Jun Yao; Bao-Jie Wang
Journal:  J Mol Neurosci       Date:  2019-08-22       Impact factor: 3.444

Review 10.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.